Unknown

Dataset Information

0

NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1?/Wnt/?-catenin signaling pathway.


ABSTRACT: BACKGROUND:Gemcitabine is widely used in the treatment of breast cancer (BC). However, the resistance to drugs remains a tough concern. The study explored the potential mechanism concerning gemcitabine resistance in triple-negative BC (TNBC) in vitro. METHODS:TNBC cells (TNBCC) and gemcitabine-resistance cell lines (GRC) were used. We investigated the sensitivity to gemcitabine responsive to regulation of Nod-like receptor protein 3 (NLRP3) expression in TNBCC in different gemcitabine concentrations. RT-PCR checked NLRP3 mRNA expression and MTT assessed the cell cytotoxicity. Gemcitabine resistance was studied in GRC exposed to 0, 1, 3, 5 nm gemcitabine after GRC were treated with NLRP3 agonist Nigericin sodium salt (NSS) or antagonist CY-09. Epithelial-to-mesenchymal transition (EMT) biomarkers were evaluated via RT-PCR and inflammasome IL-1?, ?-catenin content and GSK-3? activity were measured by ELISA methods. Last, we inactivated the signaling and examined the NLRP3, EMT mRNA expression by RT-PCR, IL-1?, ?-catenin content and GSK-3? activity by ELISA and cell cytotoxicity through MTT. RESULTS:NLRP3 up-regulation improved cell survival and reduced sensitivity to gemcitabine (P<0.05). NLRP3 had higher expression in GRC than TNBCC. GRC cell viability dropped as the gemcitabine concentration increased. NLRP3 up-regulation added to resistance to gemcitabine in GRC (P<0.05). NLRP3 agonist might induce EMT process, activate wnt/?-catenin signaling and IL-1?, while inactivation of wnt/?-catenin signaling could result in the inhibition of NLRP3, IL-1? and EMT as well as cell viability in GRC (P<0.05). CONCLUSION:NLRP3 could enhance resistance to gemcitabine via IL-1?/EMT/Wnt/?-catenin signaling, which suggested that NLRP3 antagonist CY-09 might be incorporated into gemcitabine treatment for TNBC.

SUBMITTER: Zheng Q 

PROVIDER: S-EPMC7335831 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1β/Wnt/β-catenin signaling pathway.

Zheng Qiao Q   Yao Dejiao D   Cai Yi Y   Zhou Tiecheng T  

Bioscience reports 20200701 7


<h4>Background</h4>Gemcitabine is widely used in the treatment of breast cancer (BC). However, the resistance to drugs remains a tough concern. The study explored the potential mechanism concerning gemcitabine resistance in triple-negative BC (TNBC) in vitro.<h4>Methods</h4>TNBC cells (TNBCC) and gemcitabine-resistance cell lines (GRC) were used. We investigated the sensitivity to gemcitabine responsive to regulation of Nod-like receptor protein 3 (NLRP3) expression in TNBCC in different gemcita  ...[more]

Similar Datasets

| S-EPMC5438912 | biostudies-literature
| S-EPMC5744972 | biostudies-literature
| S-EPMC3978727 | biostudies-literature
| S-EPMC10095561 | biostudies-literature
| S-EPMC8042664 | biostudies-literature
| S-EPMC5190013 | biostudies-literature
| S-EPMC8340846 | biostudies-literature
| S-EPMC7330863 | biostudies-literature
| S-EPMC7272395 | biostudies-literature
| S-EPMC7403884 | biostudies-literature